In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about any scientific advance. It is the politicized destruction of U.S. science, and the dismantling of a scientific ecosystem that has been the envy of the world since it emerged after Germany destroyed its own pre-eminence in the 1930s. Read More

Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies. Several such molecules, such as RSL3, work by inhibiting glutathione peroxidase 4 (GPX4), an enzyme that mitigates oxidative stress and on which metastatic cancer cells depend in order to undergo the epithelial-mesenchymal transition. Read More

Mondego Bio Lda has selected protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitor ZE00-0388 as its lead clinical candidate. The company is targeting initiation of a first-in-human phase I study in the first half of next year. Read More

Ipsen SA has signed an exclusive licensing agreement with Simcere Zaiming Pharmaceutical Co. Ltd. for global rights outside of Greater China for SIM-0613, an LRRC15-targeting antibody-drug conjugate developed by Simcere Zaiming for solid tumors. The program is expected to enter phase I development in the second half of next year. Read More

Researchers at Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and at Tongji University have disclosed glutaminyl-peptide cyclotransferase-like protein (QPCTL; IsoQC) and glutaminyl-peptide cyclotransferase (QPCT; QC) inhibitors reported to be useful for the treatment of cancer, obesity, aging, immunological disorders and neurological disorders. Read More

JAK2 inhibitors (JAK2i) are the standard treatment for myelofibrosis (MF), offering symptom relief and reducing spleen size. However, all FDA-approved JAK2i are type I inhibitors, which fail to eliminate the mutant MPN clone, leading many patients to treatment discontinuation. Read More

CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for SYH-2085 tablets for the treatment of uncomplicated influenza A and B in adults and adolescents age 12 years and older. Read More

Dexoligo Therapeutics has presented data for their liver-targeted siRNA DXO-1801 for the potential treatment of inflammation-driven anemia, a serious complication of chronic diseases such as chronic kidney disease, myelofibrosis or advanced solid tumors characterized by elevated pro-inflammatory cytokines where the availability for iron for erythropoiesis is limited due to increased hepcidin levels. Read More

Laekna Pharmaceutical Ningbo Co. Ltd. has synthesized compounds acting as phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer. Read More

Aché Laboratórios Farmacêuticos SA has identified compounds acting as sodium/glucose cotransporter 1 (SGLT-1), SGLT-2 and dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cardiovascular, renal and metabolic diseases. Read More

Enveda has obtained IND clearance from the FDA and commenced dosing in a phase I study of ENV-308, a once-daily oral therapy designed for chronic weight management. Read More

Signet Therapeutics Co. Ltd. has divulged transcriptional enhancer factor (TEAD) inhibitors reported to be useful for the treatment of cancer, metabolic disorders, inflammatory disorders and neurodegeneration. Read More

Jiangsu Simcere Biologics Co. Ltd. has described bispecific antibody-drug conjugates (ADC) comprising a bispecific human antibody targeting hepatocyte growth factor receptor (HGFR; MET) and epidermal growth factor receptor (EGFR; HER1; erbB1), covalently linked to a camptothecin derivative through a linker reported to be useful for the treatment of cancer. Read More

Syremis Therapeutics Ltd. has launched with $165 million in series A funding to develop novel medicines for the treatment of mental health disorders. Read More